Vnitr Lek 2022, 68(5):279-284 | DOI: 10.36290/vnl.2022.060

News in the treatment of axial spondyloarthritis

Martin ®urek, Pavel Horák
III. interní klinika - nefrologická, revmatologická a endokrinologická FN Olomouc

Axial spondyloarthritis is a rheumatic disease characterized by inflammation and bone formation causing impaired function of the spine and affected joints. Basic research has highlighted the key role of dysregulation of tumor necrosis factor α, interleukin-23 and interleukin-17 cytokine production in the etiology of axial spondyloarthritis. Tumor necrosis factor α and interleukin-17 inhibitors have been shown to be effective in clinical trials and are currently approved biological disease-modifying drugs for all disease subgroups. The presumed efficacy of IL-23 blockade has not been confirmed in two clinical trials with anti-IL-23 monoclonal antibodies. Janus kinase inhibitors appear to be a new treatment option

Keywords: axial spondyloarthritis, tumor necrosis factor α inhibitors, interleukin-17 inhibitors, interleukin-23 inhibitors, Janus kinase inhibitors.

Accepted: August 4, 2022; Published: August 22, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
®urek M, Horák P. News in the treatment of axial spondyloarthritis. Vnitr Lek. 2022;68(5):279-284. doi: 10.36290/vnl.2022.060.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Rudwaleit M, van der Heijde D, Landewe' R et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777-783. Go to original source... Go to PubMed...
    2. Lories RJ, Haroon N. Evolving concepts of new bone formation in axial spondyloarthritis: insights from animal models and human studies. Best Pract Res Clin Rheumatol. 2017;31(6):877-886. Go to original source... Go to PubMed...
    3. Regnaux JP, Davergne T, Palazzo C et al. Exercise programmes for ankylosing spondylitis. Cochrane Database Syst Rev. 2019;10:CD011321. Go to original source... Go to PubMed...
    4. Kroon FP, van der Burg LR, Ramiro S et al. Non‑steroidal antiinflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non‑radiographic axial spondyloarthritis). Cochrane Database Syst Rev. 2015;(7):CD010952. Go to original source...
    5. van der Heijde D, Ramiro S, Landewé R et al. 2016 update of the ASASEULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):78-91. Go to original source... Go to PubMed...
    6. Maxwell LJ, Zochling J, Boonen A et al. TNF‑alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015;4:CD005468. Go to original source... Go to PubMed...
    7. Karmacharya P, Duarte‑Garcia A, Dubreuil M et al. Effect of therapy on radiographic progression in axial spondyloarthritis: a systematic review and meta‑analysis. Arthritis Rheumatol. 2020;72(5):733-749.
    8. Lian F, Zhou J, Wang Y et al. Efficiency of dose reduction strategy of etanercept in patients with axial spondyloarthritis. Clin Exp Rheumatol 2018;36(5):884-890. Go to PubMed...
    9. Maxwell LJ, Zochling J, Boonen A et al. TNF‑alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015;4:CD005468. Go to original source... Go to PubMed...
    10. Baraliakos X, Braun J, Deodhar A et al. Long‑term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. RMD Open. 2019;5(2):e001005. Go to original source... Go to PubMed...
    11. Deodhar A, van der Heijde D, Gensler LS et al. Ixekizumab for patients with non‑radiographic axial spondyloarthritis (COAST‑X): a randomised, placebocontrolled trial. Lancet. 2020;395(10217):53-64. Go to original source... Go to PubMed...
    12. Wang P, Zhang S, Hu B et al. Efficacy and safety of interleukin-17 A inhibitors in patients with ankylosing spondylitis: a systematic review and meta‑analysis of randomized controlled trials. Clin Rheumatol. 2021;40(8):3053-3065. Go to original source... Go to PubMed...
    13. Deodhar A, Gensler LS, Sieper J et al. Three multicenter, randomized, double‑blind, placebo‑controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 2019;71(2):258-270. Go to original source... Go to PubMed...
    14. Baeten D, Østergaard M, Wei JC‑C et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double‑blind, placebo‑controlled, proof‑ofconcept, dose‑finding phase 2 study. Ann Rheum Dis. 2018;77(9):1295-302. Go to original source... Go to PubMed...
    15. van Tok MN, Na S, Lao CR et al. The initiation, but not the persistence, of experimental spondyloarthritis is dependent on interleukin-23 signaling. Front Immunol. 2018;9:1550. Go to original source... Go to PubMed...
    16. Gracey E, Qaiyum Z, Almaghlouth I et al. IL-7 primes IL- 17 in mucosal‑associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis. Ann Rheum Dis. 2016;75:2124-32. Go to original source... Go to PubMed...
    17. Noack M, Ndongo‑Thiam N, Miossec P. Interaction among activated lymphocytes and mesenchymal cells through podoplanin is critical for a high IL-17 secretion. Arthritis Res Ther. 2016;18:14. Go to original source... Go to PubMed...
    18. van der Heijde D, Deodhar A, Wei JC et al. Tofacitinib in patients with ankylosing spondylitis a phase II, 16 week randomised, placebo controlled study. Ann Rheum Dis. 2017;76:1340-1347. Go to original source... Go to PubMed...
    19. Maksymowych WP, van der Heijde D, Baraliakos X, et al. Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients. Rheumatology. 2018;57:1390-1399. Go to original source... Go to PubMed...
    20. Deodhar A, Sliwinska‑Stanczyk P, Xu H et al. Tofacitinib for the Treatment of Adult Patients with Ankylosing Spondylitis: Primary Analysis of a Phase 3, Randomized, Double‑blind, Placebo‑controlled Study. Abstract. ACR 2020.
    21. van der Heijde D, Song I‑H, Pangan AL et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT‑AXIS 1): a multicentre, randomised, double‑blind, placebo‑controlled, phase 2/3 trial. Lancet. 2019;394(10214):2108-2117. Go to original source... Go to PubMed...
    22. van der Heijde D, Baraliakos X, Gensler LS et al. Efficacyand safety of filgotinib, a selective Janus kinase 1inhibitor, in patients with active ankylosing spondylitis(TORTUGA): results from a randomised, placebocontrolled, phase 2 trial. Lancet. 2018;392(10162):2378-2387. Go to original source... Go to PubMed...
    23. Lee YH, Song GG. Janus kinase inhibitors for treating active ankylosing spondylitis: a meta‑analysis of randomized controlled trials. Z Rheumatol. 2022;81(1):71-76. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.